Study of Sotatercept in Newly Diagnosed Intermediate- and High-risk PAH Patients
Status:
Recruiting
Trial end date:
2028-08-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the effects of sotatercept treatment (plus
background PAH therapy) versus placebo (plus background PAH therapy) on time to clinical
worsening (TTCW) in participants who are newly diagnosed with PAH and are at intermediate or
high risk of disease progression.